SCHEMBL5455869

SCHEMBL5455869

CC(=O)Nc1cccc(Nc2nccc3c(-c4cccc(OCc5ccccc5)c4)cccc23)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.56
KMT2A Q03164 5/20 0.56
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
ABCG2 Q9UNQ0 5/20 0.52
LMNA P02545 1/20 0.51
KDM4E B2RXH2 3/20 0.48
MAPT P10636 3/20 0.48
MAPK1 P28482 1/20 0.48
CYP11B1 P15538 1/20 0.48
CYP11B2 P19099 1/20 0.48
NR1H4 Q96RI1 1/20 0.47
PTK6 Q13882 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.45
ALDH1A1 P00352 2/20 0.45
HTT P42858 1/20 0.45
ABCB1 P08183 1/20 0.45
ABCC1 P33527 1/20 0.45
MAOB P27338 1/20 0.44
HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5450768 0.91 PPIA (0.52) MEN1KMT2ANPC1RAB9AABCG2
SCHEMBL5442245 0.84 MAOB (0.51) NR1H4PTK6MAOBCTSVCTSL
SCHEMBL5440503 0.83 ABCG2 (0.54) MEN1KMT2AABCG2KDM4EMAPT
SCHEMBL5445534 0.81 ABCG2 (0.52) MEN1KMT2AABCG2LMNAMAPT
SCHEMBL5442218 0.78 ABCG2 (0.48) ABCG2PTK6PPIA
SCHEMBL10599853 0.77 MEN1 (0.79) MEN1KMT2ANPC1RAB9ALMNA
SCHEMBL28451935 0.75 BRD4 (0.58) MEN1KMT2ANPC1RAB9ALMNA
SCHEMBL7120208 0.75 EPHX1 (0.47) MEN1KMT2AMAPTALDH1A1
SCHEMBL5437465 0.73 BRAF (0.45) MEN1KMT2AABCG2MAPTSMN1; SMN2
SCHEMBL5440563 0.72 IGF1R (0.53) MAOBIGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070072901-A1 1-Amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 GLAXO GROUP LIMITED (GB) 2007-03-29 US disclosed
EP-1689718-A1 1-AMINO-ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH INAPPROPRIATE ALK5 ACTIVITY GLAXO GROUP LIMITED (GB) 2006-08-16 EP disclosed
WO-2005049577-A1 1-AMINO-ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH INAPPROPRIATE ALK5 GLAXO GROUP LIMITED (GB) 2005-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072901-A1 1-Amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 ALK, NPR3, CBR3 MEN1 2103/4885KMT2A 1370/4885NPC1 406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.